Katie Peng has more than 30 years of experience in the pharma/biotech industry managing extensive product portfolios in both the US and global markets. Since 2021, Katie has been the Chief Commercial Officer for Denali Therapeutics. She is responsible for commercializing Denali’s pipeline and for establishing a global organization to serve patients. She is a member of the executive management team and has a leadership role in shaping company strategy, culture, and vision. Katie also serves as a board member for California Life Sciences and Adicet Bio.
Prior to joining Denali, Katie was the Senior Vice President, Business Unit Head at Genentech. She was responsible for the neurology, ophthalmology, immunology, respiratory, and rare diseases portfolio. She spent almost two decades at Genentech and Roche, holding several senior leadership positions. During her tenure, Katie successfully launched multiple products in neurology, oncology, and rare diseases. Between 2012-2017, she was a General Manager for Roche in two APAC countries. Katie has broad US and global experience that spans marketing, sales, market access, medical affairs, and business planning.
Katie began her career as a research scientist at Allergan. After earning her MBA, she joined Amgen where she held several commercial roles. Katie holds a BA from the University of California, Berkeley and an MBA from the Kelley School of Business, Indiana University.
